Search

The complete chloroplast genome sequence of Camellia sinensis cultivar 'Qiancha 1' (QC1), an excellent tea plant cultivar was determined in this study. The cp genome of QC1 is 157,024 bp in length and includes a large single copy (LSC, 86,585 bp), a small single copy (SSC, 18,277 bp) and a pair of inverted repeats (IRa and IRb, 26,081 bp). The overall GC content is 37.3%. A total of 137 genes were annotated, including 92 protein coding, 37 tRNA, and eight rRNA genes. Phylogenetic analysis showed that QC1 has the closest evolutionary relationship with C. sinensis cultivar 'Anhua' from Hunan, China. The complete cp genome of QC1 provides a resource for further research on the phylogeny and taxonomy of Sect. Thea (L.) Dyer. [ABSTRACT FROM AUTHOR]

Objective: To compare the efficacy of 3/4-drugs’ group with 1-drug’s or 2-drugs’ groups in coronavirus disease 2019 (COVID-19). Methods: We included 207 patients confirmed with COVID-19. We compared the viral clearance rate and discharge rate at day 7, 14, 21 and 28, and median time of viral clearance and length of hospitalization in patients treated with 3/4, 1 or 2 drugs. Results: The viral clearance rates of the 3/4-drugs group at day 7, 14 and 21 were significantly lower than those in the 1-drug’s or 2-drugs’ groups (P < 0.05). The median viral clearance days in 3/4-drugs group (13.5 days) were longer than 1-drug’s or 2-drugs’ groups (both were 9 days) (P < 0.001). The patients’ discharge rates in the 3/4-drugs group at day 14 and 21 were significantly lower than that in the 1-drug’s or 2 drugs’ group (P < 0.05). The median length of hospitalization in the 3/4-drugs group was 17 days, which was significantly longer than 11 days in the 1-drug group and 13 days in the 2-drug group (P < 0.05). Conclusion: The efficacy of 1 or 2 antiviral drugs was similar in COVID-19, and 3/4-drug regimens were not associated with clinical improvement. Corticosteroid treatment and more serious disease were also risk factors for viral clearance and patients’discharge. [ABSTRACT FROM AUTHOR]